News | May 20, 2009

Lantheus to Build Mo-99 Medical Isotope Supply Via Supply Chain Diversification

May 20, 2009 – Lantheus Medical Imaging Inc. has signed an agreement with NTP Radioisotopes (Pty) Ltd., a subsidiary of the South African Nuclear Energy Corp. (NECSA), to manufacture and supply Lantheus with an ongoing volume of molybdenum-99 (Mo-99), a key isotope used in medical imaging procedures.

This agreement is part of Lantheus’ solution to invest in a supply chain diversification strategy and providing new solutions to address the limited and fragile global Mo-99 supply chain, as evidenced by the current NRU reactor shutdown in Canada. Under the terms of this agreement, Lantheus will receive a specified supply of Mo-99 at regular intervals from NTP, enhancing the company’s ability to meet and/or exceed customer demand. NTP has, in turn, partnered with Belgian radiochemical producer IRE to co-supply the Lantheus requirement and thereby maximize security of ongoing regular supplies of Mo-99 to Lantheus. IRE and NTP have a long and successful relationship as reliable and consistent suppliers of Mo-99 to key customers.

Global shortfalls of Mo-99 have recently impacted the availability of critical diagnostic imaging procedures, causing concern within the medical imaging industry. Mo-99 is the parent isotope of technetium-99m (Tc99m), the most widely utilized radioisotope in the world for molecular and nuclear diagnostic imaging procedures. There are only a few major suppliers of nuclear-reactor generated Mo-99 in the world. Mo-99 is primarily imported into the U.S. from aging and increasingly less reliable nuclear reactors. Recent problems within the global reactor structure have created instability in the supply of Mo-99, affecting the availability of the medical isotope to technetium generator manufacturers. Without adequate supply of Mo-99, crucial imaging tests must be canceled or postponed with potentially negative consequences for patients.

“Partnering with NTP Radioisotopes as a reliable supplier of Mo-99 will provide us with expanded access within a limited supply chain. This partnership will bring our complementary skillsets and commitment to quality and reliability together to ensure patients have uninterrupted, timely access to needed medical imaging procedures that can diagnose life-threatening conditions such as heart disease and cancer,” said Don Kiepert, president and CEO, Lantheus Medical Imaging. “Diversification of our supply chain and the introduction of new solutions in the marketplace to address the frequent worldwide medical isotope shortages is one of our foremost priorities as a company.”

“As one of the top global producers of radioisotopes, NTP is pleased to enter into this mutual alliance with Lantheus Medical Imaging to ensure continued supply of Mo-99 for use in important diagnostic tests,” said Don Robertson, managing director of NTP Radioisotopes (Pty) Ltd. “For more than 17 years, NTP has played a significant role in its contribution toward the diagnosis and treatment of illnesses.”

For more information: www.lantheus.com

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Weight-Bearing CT International Study Group Hosts  Scientific Session at AOFAS Conference
News | Computed Tomography (CT) | June 15, 2018
June 15, 2018 —The Weight-Bearing CT International Study Group will host a scientific session on the benefits of weig
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
360 Photos | 360 View Photos | June 14, 2018
This is a 360 degree image from the Canon Aquilion 64-slice...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
American Society of Neuroradiology Honors Peter Chang with Cornelius G. Dyke Memorial Award
News | Neuro Imaging | June 13, 2018
Peter Chang, M.D., current neuroradiology fellow at UCSF and recently recruited co-director of the UCI Center for...
NewYork-Presbyterian Expands Mobile Stroke Treatment Unit Fleet

Image courtesy of NewYork-Presbyterian Hospital

News | Stroke | June 11, 2018
NewYork-Presbyterian, in collaboration with Weill Cornell Medicine, Columbia University Irving Medical Center and the...
Overlay Init